|Articles|May 10, 2022

Cannabis Patient Care

  • March/April 2022
  • Volume 3
  • Issue 1
  • Pages: 8-11

Chronic Pain: Data Snapshot

Here, Tetragram shares an overview of some of the top four areas users reported on related to pain to see what type of products they are finding useful, how they are consuming it, and more.

Chronic pain can be a symptom for many patients with various illnesses. On their website, Johns Hopkins Medicine defines chronic pain as long standing pain that persists beyond the usual recovery period or occurs along with a chronic health condition. Otha Smith’s Tetragram mobile app allows users to anonymously track cannabis products as well as the conditions or symptoms they are using it for. In their most recent collection of data, users reported muscle pain, joint paint, nerve pain, muscle spasms, injury pain, headache, migraine, abdominal pain, chronic back pain, surgical pain, and more. Here, Tetragam allows us to share an overview of some of the top four areas patients reported on related to pain to see what type of products they are finding useful to help manage their pain, how they are consuming it, and more. This data relates to patients that reported muscle pain, joint pain, nerve pain, and injury pain. Some data highlights from this set include:

  • Inhalation is still the most popular consumption method among consumers with an average of 83.35% across all four symptoms reported here.
  • The average consumer is still not completely satisfied or experiencing symptom relief with an average of 35.58% of users responding with a score of 5 for the overall rating in these four symptom categories.

Muscle Pain

Patients who selected muscle pain as their primary symptom equaled 1729 sessions. Of those sessions, 32.79 reported using THC, 17.13 reported THCA, 8 reported CBD, 4.83 reported THCV, 2.9 reported CBDA, and 0.13 reported CBDV in their product.

Joint Pain

Patients who selected joint pain as their primary symptom equaled 1503 sessions. Of those sessions, 32.5 reported using THC, 16.67 reported THCA, 8.62 reported CBD, 3.99 reported THCV, 2.84 reported CBDA, and 0.06 reported CBDV in their product.

Nerve Pain

Patients who selected nerve pain as their primary symptom equaled 977 sessions. Of those sessions, 32.9 reported using THC, 16.21 reported THCA, 9.72 reported CBD, 5.02 reported THCV, 2.79 reported CBDA, and 0.03 reported CBDV in their product.

Injury Pain

Patients who selected injury pain as their primary symptom equaled 688 sessions. Of those sessions, 33.79 reported using THC, 14.98 reported THCA, 7.19 reported CBD, 3.06 reported THCV, 1.7 reported CBDA, and 0.15 reported CBDV in their product.


Related to this article

2025 Medical Cannabis Roundup
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Image | adobe.stock/Stock Rocket
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
Manipulating Cannabis Genetics: Pulling Levers to Increase  Phytochemical Composition
Cannabis genetics fundamentally dictate the plant's potential for chemical signatures, including cannabinoid and terpene profiles, and physical traits, such as yield. Cultivators use selective techniques, such as "stacking," to enhance specific compounds. Ultimately, successful cultivation involves balancing superior genetics with environmental "levers" to optimize gene expression and create targeted strains.
Image | adobe.stock/Maksim Kabakou
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!